A Multi-Center, Open-Label, Phase 1/1b Study of Escalating Doses of RO5503781 Administered Orally as 1) a Single Agent, 2) In Combination With Cytarabine, or 3) With Cytarabine and Anthracycline and 4) Assessing PK and Safety of New Optimized Formulation of RO5503781 With Cytarabine in Patients With Acute Myelogenous Leukemia (AML)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Cytarabine (Primary) ; Idasanutlin (Primary) ; Anthracyclines; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Roche
- 08 Dec 2020 Results investigating the contribution of Idasanutlin exposure variability to those findings, in particular, the relationship between exposure and toxicity and efficacy in pts with AML from NCT02545283, NCT01773408, NCT01462175 and NCT03287245 presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Results assessing minimal residual disease in relapsed/refractory AML patients treated with idasanutlin presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 01 Aug 2016 Status changed from active, no longer recruiting to completed.